Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review.

Lung cancer is the most commonly diagnosed cancer among men and it is the third ranked in women. There are two major types of lung cancer, namely, small cell lung cancer (SCLC), which accounts for ~20% of the cases, and non-small cell lung cancer (NSCLC), which is the most common. Chemotherapy and chemoradiotherapy have been used as the first-line therapies but suffer from lack of efficacy and also of several toxic adverse effects.

Expression level of and combined with exon 19 deletion in and status confer differential prognosis of lung adenocarcinoma subtypes.

Non-small cell lung cancer (NSCLC) is a lethal cancer-related disease in population. Adenocarcinoma (AC) is subclassified into several subtypes based on the new classification by the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society in 2011. Correlation between original expression of Crk-like () and anaplastic lymphoma receptor tyrosine kinase in diverse histological components of AC and epidermal growth factor receptor () or status was evaluated by immunohistochemistry and sequencing in present study.

The clinicopathological significance of hMLH1 hypermethylation in non-small-cell lung cancer: a meta-analysis and literature review.

The hMLH1 gene plays an essential role in DNA repair. Methylation of the hMLH1 gene is common in many types of cancer and can lead to the loss of hMLH1 expression. However, the association and clinicopathological significance between hMLH1 promoter hypermethylation and non-small-cell lung cancer (NSCLC) is elusive.

Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review.

Lung cancer is the leading cause of cancer-related mortality in men worldwide. Aberrant RARβ promoter methylation has been frequently investigated in non-small-cell lung carcinoma (NSCLC), the most common form of lung cancer. The aim of present study was to carry out a meta-analysis and a systematic review to evaluate clinicopathological significance of RARβ promoter hypermethylation in NSCLC.

CD3+ CD4+ and CD3+ CD8+ lymphocyte subgroups and their surface receptors NKG2D and NKG2A in patients with non-small cell lung cancer.

Background: To explore the prevalence of lymphocyte subgroups CD3+ CD4+ and CD3+ CD8+ and their surface receptors NKG2D and NKG2A in patients with non-small cell lung cancer (NSCLC).

Materials And Methods: A total of 40 patients with NSCLC were divided into different groups according to different clinical factors (TNM staging, pathological patterns and genders) for assessment of relations with CD3+ CD4+ and CD3+ CD8+ and the surface receptors NKG2D and NKG2A of T lymphocytes in peripheral blood by flow cytometry.

Results: Patients in the advanced group had evidently lower levels of CD3+ CD4+ but markedly higher levels of CD3+ CD8+ in peripheral blood than those with early lesions (p<0.

Pulmonary lobectomy combined with pulmonary arterioplasty by complete video-assisted thoracic surgery in patients with lung cancer.

Objective: To explore the feasibility of pulmonary lobectomy combined with pulmonary arterioplasty by complete video-assisted thoracic surgery (VATS) in patients with lung cancer, and summarize its surgical methods.

Materials And Methods: Twenty-one patients with lung cancer in Beijing Chest Hospital Affiliated to Capital Medical University from Feb., 2010 to Jun.

[Video-assisted thoracoscopic surgery bronchial sleeve lobectomy for lung cancer].

Objective: To discuss the feasibility of video-assisted thoracoscopic surgery(VATS) bronchial sleeve lobectomy for NSCLC,and to describe this treatment method and the major Indications.

Method: Between September 2010 and December 2012, 10 patients in our hospital underwent VATS bronchial sleeve lobectomy.The patients were one female and nine males.

[Different treatment modalities of patients with stage III lung cancer].

Objective: In order to improve the survival-rates and study the long-term therapeutic effect of stage III lung cancer patients with different treatment modalities.

Methods: From 1995 to 2004, 1921 patients of stage III lung cancer treated at our hospital were retrospectively analyzed to compare the long-term therapeutic effect of different treatment modalities. There were 606 cases in the combined therapy group (mainly surgical with combined treatment of chemotherapy & radiotherapy), 317 cases in the surgery alone group and 998 cases in the non-surgical group.

[Surgical treatment of 133 cases of multi-drug-resistant pulmonary tuberculosis].

Objective: To evaluate the clinical significance of pulmonary resection for multi-drug-resistant pulmonary tuberculosis.

Methods: The clinical data were retrospectively reviewed for patients with multi-drug-resistant pulmonary tuberculosis for which surgical resection of the lung was undertaken.

Results: From January 1980 to December 2007, 1188 patients with pulmonary tuberculosis, including 133 multi-drug resistant cases, underwent pulmonary resection in Beijing Chest Hospital.

[Impact of TNM staging and treatment mode on the prognosis of non-small cell lung cancer].

Objective: To study the impact of TNM staging and combined treatment mode on the survival of non-small cell lung cancer (NSCLC) patients.

Methods: From January 1997 to December 2002, 987 NSCLC patients were surgically treated in this hospital. Of those, 574 received combined modality therapy (surgery + chemotherapy/radiotherapy), while 413 underwent operation alone.

[Second-line Hycamtin in the treatment of lung cancer].

Objective: To discuss the therapeutic effect and toxicity of second line Hycamtin for lung cancer patients.

Methods: Ten of these 21 patients had been treated with operation. All these 21 patients received second line Hycamtin treatment; given at the dose of 1.